North America Medical Cannabis Market Size, Share & Trends Analysis Report By Product Type (Flowers, Concentrates, Topicals & Transdermal Formulations, Oils & Tinctures, Other Product Types), By Application (Oncology, Chronic Pain Management, Mental Health Management, Neurological Disease Management, Other Applications), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Country (U.S., Canada) Forecasts, 2026-2034

Market Overview

The North America Medical Cannabis Market size was valued at USD 7.39 billion in 2025 and is projected to grow from USD 8.69 billion in 2026 to reach USD 31.84 billion by 2034, growing at a CAGR of 17.6% during the forecast period 2026–2034.

Medical cannabis, also known as medical marijuana, is a herbal medication derived from Cannabis plants used to treat specific symptoms or diseases, such as cancer, chronic pain, and psychiatric disorders. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main cannabinoids extracted from this plant that provide medicinal benefits. The market is developing because of expanding R&D efforts and financial assistance from numerous private and public organizations. The market for medical cannabis is expanding because of rising chronic disease prevalence and consumer acceptance of cannabis-based medicines.

Additionally, it is anticipated that the advancement of medicinal cannabis will fuel the development of this industry over the coming years through clinical trials and judgments made by regulatory agencies in developed countries. In addition, it is anticipated that over the forecast period, the status of medicinal cannabis will improve because of clinical trials and decisions taken by regulatory agencies in developed countries. But the market is constrained by a dearth of knowledge about the advantages of medical marijuana and strict regulatory requirements.

North America Medical Cannabis Market Segmentation Analysis

By Product Type

The North America Medical Cannabis Market is segmented into Flowers, Concentrates, Topicals & Transdermal Formulations, Oils & Tinctures, and Other Product Types. Flowers include dried cannabis products used under regulated medical cannabis programs, while concentrates provide higher concentrations of cannabinoids for selected therapeutic applications. Topicals and transdermal formulations are designed for localized or systemic delivery through the skin, whereas oils and tinctures provide controlled administration and dosing flexibility. Oils & Tinctures represent an important product category because of their convenient administration, flexible dosing, and suitability for patients seeking consistent cannabinoid delivery. The availability of regulated medical cannabis products and increasing patient awareness are supporting demand across these product categories.

Growing acceptance of medical cannabis, expansion of regulated programs, increasing pharmaceutical research, and improvements in extraction and formulation technologies are supporting product diversification across North America. Flowers continue to maintain demand in markets where their medical use is permitted, while concentrates are benefiting from advancements in cannabinoid extraction and formulation. Topical and transdermal formulations are creating opportunities for localized applications, while oils and tinctures are gaining attention because of their ease of use and dosing flexibility. Continued regulatory developments, product innovation, and increasing availability of standardized formulations are expected to support further growth across product types.

Request Customizationto receive a tailored report.

By Application

The North America Medical Cannabis Market is segmented into Oncology, Chronic Pain Management, Mental Health Management, Neurological Disease Management, and Other Applications. Oncology applications include supportive management of selected symptoms associated with cancer and its treatment, while chronic pain management represents a major therapeutic area because of the widespread burden of persistent pain conditions. Mental Health Management includes selected applications associated with conditions such as anxiety and other disorders, while Neurological Disease Management covers conditions such as epilepsy, multiple sclerosis, and other neurological disorders. Other Applications include additional therapeutic areas where medical cannabis products may be used under applicable clinical and regulatory frameworks.

Chronic Pain Management represents a significant application area, supported by the high prevalence of chronic pain and growing interest in alternative therapeutic approaches. Oncology applications are also important because cannabis-based medicines may support management of selected treatment-related symptoms, while Neurological Disease Management is gaining attention as research expands around epilepsy, multiple sclerosis, and other neurological conditions. Mental Health Management is developing alongside continued research into cannabinoid-based therapies. Increasing physician awareness, expanding clinical research, patient acceptance, and the development of regulated medical cannabis programs are expected to support application growth across North America.

By Distribution Channel

The North America Medical Cannabis Market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies. Hospital pharmacies distribute medical cannabis products within healthcare institutions and are particularly relevant for physician-supervised treatment and specialized patient care. Drug Stores & Retail Pharmacies provide access to eligible patients in markets where medical cannabis distribution through pharmacies is permitted, while Online Pharmacies provide digital ordering and delivery capabilities where legally authorized. Hospital pharmacies remain an important distribution channel because of their role in prescription-based healthcare and their ability to provide professional guidance for patients receiving medical cannabis therapies.

Drug Stores & Retail Pharmacies benefit from established pharmaceutical distribution networks and increasing availability of regulated medical cannabis products, while Online Pharmacies are gaining opportunities from the expansion of digital healthcare and demand for convenient prescription fulfillment. Hospital pharmacies continue to support clinically supervised treatment and specialized care, particularly for patients receiving complex therapies. Regulatory developments, increasing digitalization of healthcare services, improvements in pharmaceutical distribution infrastructure, and growing patient demand for convenient access are expected to support continued development across distribution channels in North America.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North America medical cannabis market is segmented by country into U.S. and Canada. U.S. dominates the country market and is expected to grow at a CAGR of 17.2% during the forecast period.

The U.S. and Canada each have a separate medical cannabis market in North America. The U.S. market is expected to grow due to important research associations, regulatory guidelines, and rising product acceptability. The available capital and investments in the businesses fuel the market's expansion. The businesses with their headquarters in this area are growing in new areas.

The U.S.

The U.S. industry is expanding because of the legalization of medical cannabis in several states. Oklahoma became the 30th U.S. state to legalize medical marijuana on June 26, 2018. The first state to legalize cannabis for both recreational and medical use was South Dakota in 2020. 37 U.S. states have legalized medicinal marijuana as of May 2021. Puerto Rico, the District of Columbia, and other U.S.-dependent territories have legalized it.

The target market is expected to grow as medical cannabis is increasingly legalized in U.S. states. Additionally, it is anticipated that regulatory norm revisions will make doing business easier. Cannabis licenses in Oregon, for instance, are tied to a particular stage of the production process, such as producer, processor, distributor, laboratory, retailer, or researcher. The 70/30 regulation, which required retailers to grow 70% of the medical cannabis they sold, was abolished in Colorado. Vertical integration of medical marijuana operations is still necessary in Florida and Hawaii. Around 32 states in the U.S. passed or had bills relating to cannabis in either chamber. This legislation sought to legalize medicinal marijuana, increase the amount of THC in therapeutic products, and serve other objectives.

Canada

One of the biggest producers of medical cannabis is located in Canada. With the legalization of medical cannabis in other nations, the companies with their headquarters in Canada are growing internationally. Cronos Group (Canada) operates on five continents, whereas Canopy Growth Corporation (Canada) is in Australia, Europe, Africa, and South America, thanks primarily to its subsidiary, Spectrum Therapeutics. Aurora Cannabis, Aphria Inc., and Tilray Inc. are significant manufacturers with Canadian corporate headquarters. The announcement of combining Tilray Inc. with Aphria Inc. in 2021 will create the largest cannabis firm by revenue worldwide.

List of Key and Emerging Players in North America Medical Cannabis Market